NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.
The exercise period for warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the “Company”) ended on 18 December 2024. A total of 1,498,157 warrants were exercised for the subscription of 1,498,157 new ordinary shares, corresponding to an exercise rate of approximately 1.5 percent.
The exercise period for warrants series TO 9 took place during the period 4 – 18 December 2024. One (1) warrant series TO 9 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 0.55 per share. A total of 1,498,157 warrants were exercised, corresponding to approximately 1.5 percent of all warrants series TO 9, for the subscription of a total of 1,498,157 ordinary shares. Through the exercised warrants, Alligator Bioscience will thus receive approximately 0.8 MSEK before issue costs.
Through the warrant exercise, the number of shares in Alligator Bioscience increases by 1,498,157 ordinary shares, from a total of 758,989,086 shares to 760,487,243 shares, of which 759,708,074 are ordinary shares and 779,169 are series C shares. The share capital increases by SEK 1,198.5256 to SEK 608,389.7944. For existing shareholders who have not exercised any warrants, the dilution amounts to approximately 0.2 percent based on the number of shares in Alligator Bioscience after the exercise of warrants. The total number of votes in the Company after the exercise of the warrants amounts to 759,785,990.9.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into ordinary shares within approximately three (3) weeks.
Advisers
Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.